Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

212,041-212,070 of 319,975

filter-aware
28
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
29
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
01
Slide 1
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
02
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a linked-circle diagram to represent the interconnected nature of the company's value proposition.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a grid layout to display 8 team members with headshots, names, titles, and logos of past companies.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a three-column layout to categorize the platform's application, each with a corresponding antibody diagram.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a horizontal bar chart integrated into a table to represent clinical trial phases.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
09
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
10
The slide uses a structured list format to define the target market and unmet medical need.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
11
The slide uses a waterfall plot for response and a spider plot for longitudinal tumor burden change.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
12
Includes a spider plot for target lesion change and a Kaplan-Meier survival curve with a summary table.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
13
Includes clinical trial design details (dosing regimens, patient counts, endpoints).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
15
Includes specific clinical trial data (N=73 and N=26) and detailed breakdown of specific adverse events like constipation, neuropathy, and diarrhea.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
16
Includes detailed footnotes for data sources and medical abbreviations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
17
The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-oriented layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
19
Data cut-off Jan 4, 2023. Includes partial and complete responses.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
20
Includes waterfall plot (left) and spider plot (right) for patient response data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
21
Includes specific clinical trial safety metrics and footnotes regarding data definitions.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
22
The table displays specific drug administration schedules (mg/kg) for different cycle lengths and days.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
23
Includes abbreviations for indications (LMS, UPS, NSCLC) and trial design details.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
24
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
25
The slide uses a combination of high-level market statistics and specific clinical benchmarks to define the target opportunity.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
26
The chart highlights a specific patient case with a partial response (PR) and notes a suboptimal dose case.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
27
Uses a 2x2 grid of metrics to frame the problem space.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
28
The chart tracks % change in target lesions over time (weeks) for two specific patients.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit